BTB Korea

한국비티비 · 219750

Health Care Medical Devices · KOSDAQ

Small-cap

Market cap US$27.1M (₩37.4B)

Overview

BTB Korea makes aesthetic medical devices, equipment used for anti-aging and beauty treatments, and also distributes reagents and testing instruments through a wholesale and retail operation.

Its products serve the medical-device and biotech supply chain. The company operates two distinct divisions: a medical-device unit focused on manufacturing aesthetic equipment, and a bio unit handling distribution of reagents and testing tools. It is listed on KOSDAQ, South Korea's tech and small-cap stock exchange.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$23.2M

▲ +6.3% YoY

Operating profit · FY2025

−US$2.1M

Turned to loss

Net income · FY2025

−US$2.8M

Loss widened

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$2M(₩2.7B)	US$21.8M(₩30.1B)	US$23.2M(₩32B)
Operating profit	−US$5.3M(−₩7.3B)	US$715.9K(₩988M)	−US$2.1M(−₩2.9B)
Net income	−US$6.7M(−₩9.2B)	−US$116.4K(−₩160.7M)	−US$2.8M(−₩3.9B)

Revenue

FY2023US$2M
FY2024US$21.8M
FY2025US$23.2M

Operating profit

FY2023−US$5.3M
FY2024US$715.9K
FY2025−US$2.1M

Net income

FY2023−US$6.7M
FY2024−US$116.4K
FY2025−US$2.8M

Key ratios (FY2025)

ROE

-16.2%

Debt/Eq

82.0%

Op. margin

-8.9%

Net margin

-12.3%

Rev. YoY

▲ +6.3%

Why it matters

The current company was formed when GTG Wellness absorbed Dongin Biotech through a court-supervised restructuring merger, then rebranded as BTB Korea.

Price charts coming soon

Interactive price history isn't here yet. Would you use it?